GlassScriptPhysician profile
Charles Vincent Mullen
NPI 1447358478
$5,209.14
in general payments reported to CMS, 2019-2025
42 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $607 · 2021: $841 · 2022: $976 · 2023: $599 · 2024: $102 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $528.51 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $515.99 | 2019-2025 | Tezspire, Fasenra, Symbicort |
| Electromed, INC. | $490.31 | 2019-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.37 | 2019-2025 | Ofev |
| Insmed, INC. | $302.52 | 2019-2022 | |
| Philips North America LLC | $296.49 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $288.62 | 2019-2023 | Dupixent |
| United Therapeutics Corporation | $260.74 | 2019-2025 | Tyvaso |
| Genzyme Corporation | $254.11 | 2019-2025 | |
| Genentech USA, INC. | $234.92 | 2019-2023 | Esbriet, Xolair |
| Grifols USA, LLC | $212.01 | 2019-2023 | Xembify |
| Mylan Specialty L.P. | $143.03 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $118.08 | 2019-2023 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $93.15 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $89.79 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mullen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.